1,721,006 research outputs found
Hypertrophic cardiomyopathy risk scoring for sudden cardiac death in paediatrics, adolescents, and adults: stuck on the puzzle of clinical, imaging, and genetic features
No full textEditorial commentary: Heart failure home monitoring: Are we monitoring the patient or the disease?
No full text
Cardiovascular risk stratification in young women: the pivotal role of pregnancy
Full text linkquantification of cardiovascular risk in young wome
Challenges in Modeling and Interpreting Multivariable Linear Relationships From Observational Data of Cardiac Function Utilizing Speckle Tracking Echocardiography
No full textThe association between cardiovascular diseases and depressive symptoms in adults: the classic {\textquotedblleft}chicken or egg{\textquotedblright} causality
Full text linkThe role of physical exercise in cancer therapy-related CV toxicity
No full textCardiovascular diseases (CVD) and cancer are among the leading causes of mortality in high-income countries.In recent years, relevant improvements in managing oncologic diseases, including timely diagnosis and treatment, have led to an increase in patient’s long-term survival. On the other hand, this prolonged life expectancy also determined an escalation in the prevalence of the comorbidities potentially associated with cancer therapy administration, which from a cardiovascular (CV) standpoint are comprehensively referred with the term cancer therapy-related cardiovascular toxicity (CTR-CVT). According to the latest International Cardio-Oncology Society (IC-OS) consensus statement, CTR-CVT can be classified as: 1) symptomatic or asymptomatic cancer therapy-related cardiovascular dysfunction (CTRCD), 2) immune-checkpoint inhibitors (ICI) myocarditis, 3) asymptomatic or symptomatic vascular toxicity, 4) arterial hypertension, and 5) cardiac arrhythmias
Dilated cardiomyopathy following use of xenadrine EFX
No full textWe describe a case of a 35-year-old man presented at the emergency room of our institution with acute onset of dyspnea and dizziness. He was a body builder and had been using Xenadrine EFX for weight loss reduction. The laboratory analyses were normal. A chest radiograph showed an enlarged cardiac silhouette with clear lung fields. Transtoracic two-dimensional color Doppler echocardiography revealed a diffuse hypokinesia with a marked decreased in systolic function and a high teledyastolic diameter. This case document the possible relation to use of Xenadrine EFX for weight loss and the recurrence of dilated cardiomyopathy
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
